Bruker Corporation Earnings Recaps
Q1 2026
May 7, 2026
Bruker shares jumped 15% after the company delivered better-than-expected bookings growth in key AI-driven segments and reaffirmed its full-year outlook despite ongoing organic revenue challenges and margin pressure.
Key takeaways
- Q1 2026 revenue was $823 million, up 2.7% year-over-year, driven by an FX tailwind (4.5%) and acquisitions (2.6%), offsetting a 4.4% organic revenue decline.
- The Bruker Scientific Instruments (BSI) segment showed 5% organic revenue decline but offset by high single-digit organic bookings growth, led by AI-driven semiconductor metrology and scientific software/digitization businesses each growing bookings over 20%.
- BEST segment reported 3% organic revenue growth and secured approximately $680 million in multi-year orders across research instruments and superconductors.
- Non-GAAP gross margin declined to 50% and operating margin to 10.2%, pressured by currency headwinds, although both were still better than expectations.
- Non-GAAP EPS of $0.31 declined versus prior year’s $0.47 but beat prior expectations; management expects momentum to return to organic revenue growth in Q2 and beyond.
Q3 2025
Nov 5, 2025
Bruker Corporation reported third-quarter 2025 revenues of $860.5 million, a slight decrease year-over-year but showing sequential improvement in organic bookings, particularly in the biopharma sector.
Key takeaways
- Organic bookings grew mid-single digits, with high teen percentage growth in government and academic markets, signaling a potential turnaround.
- Third-quarter non-GAAP operating margin improved sequentially to 12.3%, from 9.0% in Q2 2025, despite lower year-over-year revenue absorption.
- Currency fluctuations contributed a 2.9% tailwind; however, organic revenue declined 4.5% year-over-year, indicating ongoing challenges in the scientific instruments segment.
- Cost savings initiatives are on track to meet goals of $100 million to $120 million, expected to bolster margins and EPS growth in 2026.